menu
    • menu

    Company profile for Immunoforge

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Professional team focusing on metabolic disease and cancer. We have an innovative solution for sarcopenia based on our drug repurposing patents. We have a strong kinase inhibitor pipeline for genomically defined rare cane We aim to be a small, but fast fish with a huge impact on our target area.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Immunoforgekorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    307-1, 105-1 Bldg, Seoul National Univ., 1 Gwanak-ro, Gwanak-gu, Seoul 08826
    Telephone
    Telephone
    +82-70-7721-0755
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immunoforge.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immunoforge To Partner Strategically At Bio-Europe Spring 2026
    Immunoforge To Partner Strategically At Bio-Europe Spring 2026

    12 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunoforge-to-conduct-strategic-partnering-at-bio-europe-spring-2026-302712139.html

    PR NEWSWIRE
    12 Mar 2026
    Share Share
    Immunoforge Hosts Partnering Meetings At J.P. Morgan Health Conf
    Immunoforge Hosts Partnering Meetings At J.P. Morgan Health Conf

    01 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunoforge-to-host-strategic-partnering-meetings-during-jp-morgan-healthcare-conference-2026-302650146.html

    PR NEWSWIRE
    01 Jan 2026
    Share Share
    ImmunoForge's IND Approval For Pemziviptadil Ph 2 Trial & KF1601 Ph 1
    ImmunoForge's IND Approval For Pemziviptadil Ph 2 Trial & KF1601 Ph 1

    14 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunoforge-receives-ind-approval-for-phase-2-clinical-trial-of-pemziviptadil-for-dmd-cardiomyopathy-treatment-from-fda-and-kf1601-a-chronic-myeloid-leukemia-treatment-phase-1-clinical-trial-ind-approved-by-mfds-302349040.html

    PR NEWSWIRE
    14 Jan 2025
    Share Share
    ImmunoForge Doses First Patient in Phase 2 Clinical Trial of Froniglutide
    ImmunoForge Doses First Patient in Phase 2 Clinical Trial of Froniglutide

    17 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunoforge-doses-first-patient-in-phase-2-clinical-trial-of-froniglutide-for-dermatomyositispolymyositis-301958194.html

    PR NEWSWIRE
    17 Oct 2023
    Share Share
    ImmunoForge Expands Drug Development Licensing Agreement with Duke University
    ImmunoForge Expands Drug Development Licensing Agreement with Duke University

    18 May 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/immunoforge-expands-drug-development-licensing-agreement-with-duke-university-301828243.html

    PR NEWSWIRE
    18 May 2023
    Share Share
    Immunoforge Inc. receives U.S. FDA ODD for Treatment of Polymyositis
    Immunoforge Inc. receives U.S. FDA ODD for Treatment of Polymyositis

    27 Sep 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/immunoforge-inc-receives-us-fda-odd-for-treatment-of-polymyositis-301384587.html

    PRNEWSWIRE
    27 Sep 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search